Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4127-4132

  Sader, Helio S ^a   Fey, Paul D ^b   Fish, Douglas N ^c   Limaye, Ajit P ^d   Pankey, George ^e   Rahal, James ^f   Rybak, Michael J ^g   Snydman, David R ^h   Steed, Lisa L ⁱ   Waites, Ken ^j   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

^f NEW YORK HOSPITAL QUEENS   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CLONE; DRUG POTENCY; HOSPITAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; WILD TYPE;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ELECTROPHORESIS, GEL, PULSED-FIELD; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; UNITED STATES; VANCOMYCIN;

EID: 70349345819     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00616-09     Document Type: Article

References (17)

1. Alos, J. I., A. Garcia-Canas, P. Garcia-Hierro, and F. Rodriguez-Salvanes. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
2. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07-A7. Approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. CLSI. 2009. Performance standards for antimicrobial susceptibility testing. M100-S19. 19th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Feil, E. J., J. E. Cooper, H. Grundmann, D. A. Robinson, M. C. Enright, T. Berendt, S. J. Peacock, J. M. Smith, M. Murphy, B. G. Spratt, C. E. Moore, and N. P. Day. 2003. How clonal is Staphylococcus aureus? J. Bacteriol. 185:3307-3316.
5. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Int. Med. 166:2138-2144.
6. Holmes, R. L., and J. H. Jorgensen. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52:757-760.
7. Jones, R. N. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl. 1):S13-S24.
8. Kollef, M. H. 2007. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45(Suppl. 3):S191-S195.
9. Liu, C., C. J. Graber, M. Karr, B. A. Diep, L. Basuino, B. S. Schwartz, M. C. Enright, S. J. O'Hanlon, J. C. Thomas, F. Perdreau-Remington, S. Gordon, H. Gunthorpe, R. Jacobs, P. Jensen, G. Leoung, J. S. Rumack, and H. F. Chambers. 2008. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin. Infect. Dis. 46:1637-1646.
10. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
11. Neoh, H. M., S. Hori, M. Komatsu, T. Oguri, F. Takeuchi, L. Cui, and K. Hiramatsu. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6:13.
12. Robert, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506-510.
13. Soriano, A., F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
14. Stefani, S., and P. E. Varaldo. 2003. Epidemiology of methicillin-resistant staphylococci in Europe. Clin. Microbiol. Infect. 9:1179-1186.
15. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
16. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.
17. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886.